title: The central and basolateral amygdala are critical sites of neuropeptide Y/Y2 receptor-mediated regulation of anxiety and depression.
abstract: Anxiety is integrated in the amygdaloid nuclei and involves the interplay of the amygdala and various other areas of the brain. Neuropeptides play a critical role in regulating this process. Neuropeptide Y (NPY), a 36 aa peptide, is highly expressed in the amygdala. It exerts potent anxiolytic effects through cognate postsynaptic Y1 receptors, but augments anxiety through presynaptic Y2 receptors. To identify the precise anatomical site(s) of Y2-mediated anxiogenic action, we investigated the effect of site-specific deletion of the Y2 gene in amygdaloid nuclei on anxiety and depression-related behaviors in mice. Ablating the Y2 gene in the basolateral and central amygdala resulted in an anxiolytic phenotype, whereas deletion in the medial amygdala or in the bed nucleus of the stria terminalis had no obvious effect on emotion-related behavior. Deleting the Y2 receptor gene in the central amygdala, but not in any other amygdaloid nucleus, resulted in an added antidepressant-like effect. It was associated with a reduction of presumably presynaptic Y2 receptors in the stria terminalis/bed nucleus of the stria terminalis, the nucleus accumbens, and the locus ceruleus. Our results are evidence of the highly site-specific nature of the Y2-mediated function of NPY in the modulation of anxiety- and depression-related behavior. The activity of NPY is likely mediated by the presynaptic inhibition of GABA and/or NPY release from interneurons and/or efferent projection neurons of the basolateral and central amygdala.
authors.affiliation: Department of Pharmacology, Medical University Innsbruck, 6020 Innsbruck, Austria. ramon.tasan@i-med.ac.at
authors.forename: Ramon O
authors.initials: RO
authors.lastname: Tasan
authors.forename: Ngoc Khoi
authors.initials: NK
authors.lastname: Nguyen
authors.forename: Stefan
authors.initials: S
authors.lastname: Weger
authors.forename: Simone B
authors.initials: SB
authors.lastname: Sartori
authors.forename: Nicolas
authors.initials: N
authors.lastname: Singewald
authors.forename: Regine
authors.initials: R
authors.lastname: Heilbronn
authors.forename: Herbert
authors.initials: H
authors.lastname: Herzog
authors.forename: Günther
authors.initials: G
authors.lastname: Sperk
mesh_terms: D000679:Amygdala / Q000378:metabolism / Q000502:physiology*; D000818:Animals; D001007:Anxiety / Q000235:genetics* / Q000378:metabolism / Q000503:physiopathology; D003863:Depression / Q000235:genetics* / Q000378:metabolism / Q000503:physiopathology; D004195:Disease Models, Animal; D008125:Locus Coeruleus / Q000378:metabolism; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D009478:Neuropeptide Y / Q000378:metabolism / Q000502:physiology*; D017476:Receptors, Neuropeptide Y / Q000235:genetics* / Q000502:physiology*; D012686:Septal Nuclei / Q000378:metabolism / Q000502:physiology
chemical_list: D009478:Neuropeptide Y; D017476:Receptors, Neuropeptide Y; C095889:neuropeptide Y2 receptor
references.citation: Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):2320-5
references.pmid: 11842206
references.citation: Pharmacol Biochem Behav. 2002 Mar;71(3):419-23
references.pmid: 11830176
references.citation: Pharmacol Biochem Behav. 1980 Aug;13(2):167-70
references.pmid: 6106204
references.citation: Psychopharmacology (Berl). 1985;85(3):367-70
references.pmid: 3923523
references.citation: Arch Gen Psychiatry. 2005 Jun;62(6):593-602
references.pmid: 15939837
references.citation: Methods. 2002 Oct;28(2):158-67
references.pmid: 12413414
references.citation: Mol Cell Neurosci. 2008 Nov;39(3):491-8
references.pmid: 18790060
references.citation: Psychopharmacology (Berl). 2008 Jan;195(4):547-57
references.pmid: 17891380
references.citation: Trends Neurosci. 1998 Aug;21(8):323-31
references.pmid: 9720596
references.citation: J Neurosci. 1996 Dec 1;16(23):7711-24
references.pmid: 8922427
references.citation: Ann N Y Acad Sci. 2003 Apr;985:185-205
references.pmid: 12724159
references.citation: Psychopharmacology (Berl). 1987;92(2):180-5
references.pmid: 3110839
references.citation: Behav Brain Res. 2003 May 15;141(2):251-5
references.pmid: 12742262
references.citation: Horm Behav. 1997 Jun;31(3):197-211
references.pmid: 9213134
references.citation: Prog Neurobiol. 2003 Jun;70(2):83-244
references.pmid: 12927745
references.citation: J Neurosci. 2008 Feb 6;28(6):1374-84
references.pmid: 18256257
references.citation: Neurosci Biobehav Rev. 2001 May;25(3):261-73
references.pmid: 11378180
references.citation: Neurosci Lett. 1989 May 22;100(1-3):53-8
references.pmid: 2569703
references.citation: Brain Res Brain Res Rev. 2001 Dec;38(1-2):79-128
references.pmid: 11750928
references.citation: J Chem Neuroanat. 2000 Dec;20(3-4):327-37
references.pmid: 11207429
references.citation: Eur J Neurosci. 2003 Jul;18(1):143-8
references.pmid: 12859347
references.citation: Neuropharmacology. 2006 Oct;51(5):1013-22
references.pmid: 16904135
references.citation: Br J Pharmacol. 1991 Jan;102(1):41-4
references.pmid: 1646061
references.citation: J Neurosci. 1988 Jul;8(7):2517-29
references.pmid: 2854842
references.citation: J Neurosci. 1993 Jan;13(1):73-86
references.pmid: 8423484
references.citation: J Neurosci. 2001 Aug 1;21(15):5804-12
references.pmid: 11466452
references.citation: Neuroscience. 2009 Feb 18;158(4):1717-30
references.pmid: 19121371
references.citation: Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4280-5
references.pmid: 15024126
references.citation: J Comp Neurol. 2006 Nov 20;499(3):357-90
references.pmid: 16998904
references.citation: Neuropsychopharmacology. 1993 Jun;8(4):357-63
references.pmid: 8099792
references.citation: Regul Pept. 1995 Oct 20;59(2):201-5
references.pmid: 8584755
references.citation: Peptides. 2006 Dec;27(12):3202-7
references.pmid: 16959374
references.citation: Brain Res. 1989 Oct 23;500(1-2):37-45
references.pmid: 2575006
references.citation: Brain Res. 2000 Jun 16;868(1):79-87
references.pmid: 10841890
references.citation: Peptides. 1998;19(2):359-63
references.pmid: 9493869
references.citation: J Neurochem. 1991 Feb;56(2):525-30
references.pmid: 1988555
references.citation: Brain Res Brain Res Rev. 2001 Dec;38(1-2):192-246
references.pmid: 11750933
references.citation: Science. 1993 Jan 22;259(5094):528-31
references.pmid: 8380941
references.citation: Brain Res. 2005 Feb 21;1035(1):24-31
references.pmid: 15713273
references.citation: J Psychopharmacol. 2008 Aug;22(6):633-41
references.pmid: 18308797
references.citation: Mol Ther. 2003 Jun;7(6):839-50
references.pmid: 12788658
references.citation: J Comp Neurol. 1986 Sep 15;251(3):349-62
references.pmid: 2429995
references.citation: Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8938-43
references.pmid: 12072562
references.citation: Psychopharmacology (Berl). 1989;97(2):277-9
references.pmid: 2567028
references.citation: Behav Pharmacol. 1995 Apr;6(3):215-222
references.pmid: 11224329
references.citation: Ann N Y Acad Sci. 2003 Apr;985:1-21
references.pmid: 12724144